ImClone, Merck Reach Deal Over Erbitux

Law360, New York (July 20, 2006, 12:00 AM EDT) -- New York-based ImClone Systems Inc. and Germany-based Merck KGaA have agreed to amend a 1998 development and licensing agreement that covers the blockbuster cancer drug Erbitux and other epidermal growth factor receptor, or EGFR, targeted antibodies.

Under the terms of the deal, which was announced Thursday, ImClone gave Merck permission to sublicense certain intellectual property rights to Japanese drug maker Takeda Pharmaceutical Co.

Takeda and Merck had signed an alliance last September regarding the anti-EGFR antibody Matuzumab.

“These agreements will allow Merck and Takeda to move...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.